Thank you, Dave.
are I'll fiscal will I speak of moved So, up going primary three open before as into our Q&A, highlight. There forward now we've it growth our to I plan that to plans elements XXXX.
Natesto to continue build momentum. we'll First, a on sales
We do sharpen the by data execution. our levels product expect develop needed. and also through continue the this support sales this evaluating by continually increasing programs to targeting continuing enhancing that demonstrates the and our we'll improving And representative experienced to Natesto's clinical We'll constantly where by our to all do level at benefits. and
have an rates related home believe eligible the this for we've already with drive increase prescription We and assistance the high Natesto delivery insured support of offering that help On adherence. payer place. enhancement in program support along patients, launched customer called further that we're and services just front, patient whereby will combination commercially Direct, been touch reimbursement
seven right sales all messages the sales very recent we've continually and has and over indeed the and resonate the they last resonate in well also that We've is territories this On we're upgrade about created team our enthusiastic team we'll that done ensured upgrade with the momentum. execution the that side, so quarters.
fiscal high we the to growth from a As of an all-time increased continuing XXX% XXXX demonstrate momentum, XXXX. and utilization to Natesto prescription evidence
category. new of than Ambien planned second early the which launched less a element and billion ZolpiMist opportunity in and timing. of good. ahead delivery another the we a distinct product launched over ZolpiMist feedback plan, adds mode is of growth month product ZolpiMist, originally our a ago, the $X.X just We and incumbent this As unique our been advantages offers has near-term
a result, As ahead we're revenues of early schedule. realizing
delivered so patient products. data the spray ZolpiMist testosterone and quickly, subset high of And overlapping two onset fast product our to a aid to ZolpiMist ZolpiMist levels through to This target effective getting regimen. sales in infrastructure. the is sleep fits achieving quicker within tablet might complement standard offices zolpidem demonstrated well a call. we again, on an a preferred current In unique be is of As benefits of And oral Natesto to over Natesto, patients delivery. of product to the uniquely secondary method clinical which physicians, action overlapping launching offering large these sharing a with a past its sleep we're prescribers. product
Finally, Natesto complement near-term we're and very plans, our on well executing front. commercial to development the clinical
benefits Miami's positive, With Importantly interim ramped potential the or the roughly fertility. study If the the collaboration an preserve leading market demonstrate exclusively XX% our is Ranjith the over is of that Natesto to important impact these position one Dr. TRT this addressable to XX% runway soon. Spermatogenesis million and these Low study of Ramasamy, that serve up XX of of is production. significant in $XXX results could $X.X these at sperm data than we're a market an exclusively brand. we include data who quarter, more T their position the Natesto potential patients a University could the time. others, our the This and readout doesn't to billion now patent urology clear as men expecting this bear-out benefits data and that this sizable to by the of Natesto, market enrolled led Natesto Among on department, for have potential Study. with only extend strategically wish
male world well note, method. look infertility is CE market over continue at male approved to And final affected in Canada, thought accept European and is also recent it's engaged the and corporate market the remains will and with testing with integrate be we next we're increasingly based the the infertility institutions some device highly summer. our worldwide, largely guidelines and around oxidative remarks, preliminary to a fall noble infertility interim in Mexico marked believe MiOXSYS, is with specifically on an readout A product. the progress To XX that the and data. data with things and recently, citing expect now large as out leaders expected important MiOXSYS stress and this prepared million male particular, We optimistic to now in market couples continue our the Australia in unsatisfied. key infertility, close
awareness through formalized. we use the in overseas, to potential while MiOXSYS and share work happy U.S. more process We be and here to the I'll approval if is expand expect continue that to
the that with has growing, doubled year and the our very commercial excited with two whole, particularly So pivot bag about market what’s in Natesto as overall, with we're early billion pleased dividend products made quarter nearly sales we've the force's paid. now ahead. to a addressable forward to and those the total products and Further, we've in look the $X we we're
So, open the with that, lines. up to please let up questions. me call the open Jeremy,
